William Blair initiated coverage on Cabaletta Bio with a new price target
$CABA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
William Blair initiated coverage of Cabaletta Bio with a rating of Outperform and set a new price target of $38.00